A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus (clinicaltrials.gov) - Sep 23, 2026 - P2 | N=24 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Pediatrics • Systemic Lupus Erythematosus
|